Morgan Stanley Downgrades Halozyme Therapeutics

Nov 11, 2026, 9:35 AM ETOpinionRead the original at marketscreener.com

Neutral

Morgan Stanley cut Halozyme's rating from Overweight to Equalweight, but raised its target from $105 to $109. These changes point opposite ways, so the report does not clearly change Halozyme's outlook.

HALO · Halozyme Therapeutics, Inc.

AI read · Neutral

The AI's read

The lower rating points to less confidence in Halozyme's shares. The higher target points the other way. Morgan Stanley gave no reason for either change, so this report alone does not show a clear change in the company's outlook.

Get alerts for HALO

Follow Halozyme Therapeutics, Inc. (HALO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for HALO

Free on the App Store and Google Play, or on the web.